The World's First mRNA Lung Cancer Vaccine Starts Clinical Trials in 7 Countries

TapTechNews August 24th news, The Guardian of the UK published a blog post yesterday (August 23rd), The world's first mRNA lung cancer vaccine has started clinical trials in 7 countries and regions. Experts praise this vaccine for its 'groundbreaking' potential to save the lives of thousands of people.

TapTechNews note: Lung cancer is the most major cause of cancer death in the world, with about 1.8 million people dying from lung cancer every year, and the survival rate of advanced lung cancer patients (tumors have already spread) is particularly low.

The world's first mRNA lung cancer vaccine is named BNT116, produced by BioNTech, aiming to treat the most common non-small cell lung cancer (NSCLC), which can capture and kill cancer cells and then prevent them from recurring.

As the first human study of BNT116, the phase 1 clinical trial has been launched in 34 research institutions in 7 countries including the UK, the US, Germany, Hungary, Poland, Spain and Turkey.

There are six vaccination sites in the UK, located in England and Wales respectively. The first batch of UK patients vaccinated have received the first dose of the vaccine this Tuesday.

This therapy uses messenger ribonucleic acid (mRNA), similar to the Covid-19 vaccine, by showing tumor markers from NSCLC to the immune system to stimulate the body to fight against cancer cells expressing these markers.

Unlike chemotherapy, the purpose of this therapy is to strengthen the patient's immune response to cancer without damaging healthy cells.